Dr. William Wierda from the MD Anderson Cancer Center was interviewed about the pipeline of new targeted therapies for CLL at the 18th International Congress On Hematologic Malignancies held in New York City in February 2014. TAKE AWAY POINTS: The major groups of inhibitors target BTK or phosphatidylinositol 3-kinase
In part two of my interview from ESH in November 2014 from Greece with Professor Stilgenbauer of the University of Ulm, Germany, we go deeper into predictive and prognostic factors that we covered in part one and introduce new subjects. I recommend you take a look at it if you haven’t
In November, 2014, I attended a meeting in Thessaloniki, Greece organized by the European School of Hematology (ESH), ESH 2014: International Conference on New Concepts in B Cell Malignancies: From molecular pathogenesis to personalized treatment. This video interview discussing predictive and prognostic markers in chronic lymphocytic leukemia (CLL) is
I am introducing a new subject, medication adherence, or the importance of taking our medications as prescribed. As C. Everett Koop stated, “Drugs don’t work in patients who don’t take them.” What we call this simple behavior has been undergoing some changes as we have shifted from the more paternal
Patients in the BR arm are allowed to crossover While this press release from Pharmacyclics broadens the potential role of ibrutinib in treating CLL and improves on an already strong chemo-immunotherapy option, one other small but vital piece of news was not included in most of the media coverage.
Take Away Points: Cancer by its nature is genomic unstable. Over time it acquires more mutations. New clones and sub-clones can arise over time. Therapy can influence the balance and evolution of the clonal and sub-clonal populations. Preface: Hematology in general and CLL specifically are full of jargon and
Take Away Points: CLL evolves drastically over time, but the seeds of the population that leads to resistance and relapse may be present from the very start. There is more to the story than the cancer itself. CLL’s microenvironment and host immune system’s response also evolve. “There has never
While we are not primarily focused on the corporate landscape in CLL, it makes sense to stay abreast of the business news that might influence what drugs get to market and how fast, what combinations are explored in clinical trials, what’s it will eventually cost, how good is insurance